Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene FLT3
Variant Q575del
Impact List deletion
Protein Effect gain of function
Gene Variant Descriptions FLT3 Q575del results in the deletion of an amino acid in the juxtamembrane domain of the Flt3 protein at amino acid 575 (PMID: 14759363). Q575del confers a gain of function to the Flt3 protein as demonstrated by activation of Stat5, Akt, and Erk1/2 signaling and IL3-independent growth in cultured cells (PMID: 33914060).
Associated Drug Resistance
Category Variants Paths

FLT3 mutant FLT3 act mut FLT3 Q575del

FLT3 mutant FLT3 exon14 FLT3 Q575del

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_004119.2
gDNA chr13:g.28034194_28034196delCTG
cDNA c.1724_1726delAGC
Protein p.Q575del
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_004119.2 chr13:g.28034194_28034196delCTG c.1724_1726delAGC p.Q575del RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FLT3 Q575del hematologic cancer sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) decreased downstream signaling and proliferation in transformed cells expressing FLT3 Q575del in culture (PMID: 33914060). 33914060
FLT3 Q575del hematologic cancer sensitive Sorafenib Preclinical - Cell culture Actionable In a preclinical study, Nexavar (sorafenib) decreased downstream signaling and proliferation in transformed cells expressing FLT3 Q575del in culture (PMID: 33914060). 33914060
FLT3 Q575del hematologic cancer sensitive Lestaurtinib Preclinical - Cell culture Actionable In a preclinical study, Lestaurtinib (CEP-701) decreased downstream signaling and proliferation in transformed cells expressing FLT3 Q575del in culture (PMID: 33914060). 33914060
FLT3 Q575del hematologic cancer sensitive AG1295 Preclinical - Cell culture Actionable In a preclinical study, AG1295 decreased downstream signaling and proliferation in transformed cells expressing FLT3 Q575del in culture (PMID: 33914060). 33914060
FLT3 Q575del hematologic cancer sensitive Crenolanib Preclinical - Cell culture Actionable In a preclinical study, Crenolanib (CP-868596) decreased proliferation in transformed cells expressing FLT3 Q575del in culture (PMID: 33914060). 33914060
FLT3 Q575del hematologic cancer sensitive Quizartinib Preclinical - Cell culture Actionable In a preclinical study, Vanflyta (quizartinib) decreased proliferation in transformed cells expressing FLT3 Q575del in culture (PMID: 33914060). 33914060
FLT3 Q575del hematologic cancer sensitive Ponatinib Preclinical - Cell culture Actionable In a preclinical study, Iclusig (ponatinib) decreased proliferation in transformed cells expressing FLT3 Q575del in culture (PMID: 33914060). 33914060
FLT3 Q575del hematologic cancer sensitive Sunitinib Preclinical - Cell culture Actionable In a preclinical study, Sutent (sunitinib) decreased proliferation in transformed cells expressing FLT3 Q575del in culture (PMID: 33914060). 33914060
FLT3 Q575del hematologic cancer sensitive Tamatinib Preclinical - Cell culture Actionable In a preclinical study, Tamatinib (R406) decreased proliferation in transformed cells expressing FLT3 Q575del in culture (PMID: 33914060). 33914060
FLT3 Q575del hematologic cancer sensitive Linifanib Preclinical - Cell culture Actionable In a preclinical study, Linifanib (ABT-869) decreased proliferation in transformed cells expressing FLT3 Q575del in culture (PMID: 33914060). 33914060
FLT3 Q575del hematologic cancer sensitive KW-2449 Preclinical - Cell culture Actionable In a preclinical study, KW-2449 decreased proliferation in transformed cells expressing FLT3 Q575del in culture (PMID: 33914060). 33914060
FLT3 Q575del acute myeloid leukemia predicted - sensitive Cytarabine + Daunorubicin + Gilteritinib Case Reports/Case Series Actionable In a clinical case study, induction therapy with Cytosar-U (cytarabine) and Cerubidine (daunorubicin) combined with Xospata (gilteritinib) resulted in complete remission in a patient with acute myeloid leukemia harboring FLT3 Q575del (PMID: 33914060). 33914060